Synthetic Methods for Chemo- and Site-selective Bioconjugation in Proteins

Asahi Kasei Pharma, a global pharmaceutical company, is seeking chemical conjugation methods for N- or C-terminal specific protein modifications, as well as synthetic methods for chemo-selective and site-selective bioconjugation, including intermediate-site selective (e.g. Lysine-specific) bioconjugation.

Approaches of interest:

• High-yield protein production methods scalable for GMP production
• Stable bond formation in buffered conditions
• Traceless affinity compound methods to improve selectivity and conversion
• Techniques with experimental data on model proteins, reaction sites, conversion rates, and selectivity

Out of scope:

• Uncontrolled reactions at multiple sites

 Developmental stage of interest: 

Opportunities from basic research to Phase III, with quantitative data using multiple model proteins to confirm conversion rate, selectivity, and isolated yield.